Terms: = Ovarian cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Diagnosis
17 results:
1. Linear IgA bullous dermatosis associated with immunotherapy.
Momin B; Nguyen TF; Glade D; Messer A
Dermatol Online J; 2023 Dec; 29(6):. PubMed ID: 38478666
[TBL] [Abstract] [Full Text] [Related]
2. Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
[TBL] [Abstract] [Full Text] [Related]
3. Application of Immune Checkpoint Inhibitors in Gynecological cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
Lee SM; Lee S; Cho HW; Min KJ; Hong JH; Song JY; Lee JK; Lee NW
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674491
[TBL] [Abstract] [Full Text] [Related]
4. Targeting pd-1/PD-L1 axis as new horizon for ovarian cancer therapy.
Khatoon E; Parama D; Kumar A; Alqahtani MS; Abbas M; Girisa S; Sethi G; Kunnumakkara AB
Life Sci; 2022 Oct; 306():120827. PubMed ID: 35907493
[TBL] [Abstract] [Full Text] [Related]
5. Vogt-Koyanagi-Harada syndrome-like uveitis after nivolumab administration as a treatment for ovarian cancer.
Hwang GE; Lee JW; Jeon S; Cho IH; Kim HD
Doc Ophthalmol; 2022 Apr; 144(2):153-162. PubMed ID: 34997406
[TBL] [Abstract] [Full Text] [Related]
6. Biomarkers of Central Nervous System Involvement from Epithelial ovarian cancer.
Scotto G; Borella F; Turinetto M; Tuninetti V; Valsecchi AA; Giannone G; Cosma S; Benedetto C; Valabrega G
Cells; 2021 Dec; 10(12):. PubMed ID: 34943916
[TBL] [Abstract] [Full Text] [Related]
7. Clinical and pathological analysis of companion diagnostic testing of microsatellite instability-high for pembrolizumab in gynaecologic malignancy.
Takeda T; Tsuji K; Kobayashi Y; Banno K; Aoki D
Jpn J Clin Oncol; 2022 Feb; 52(2):128-133. PubMed ID: 34750611
[TBL] [Abstract] [Full Text] [Related]
8. Infiltrating T lymphocytes and programmed cell death protein-1/programmed death-ligand 1 expression in endometriosis-associated ovarian cancer.
Nero C; Romito I; Spadola S; Romito A; Turco LC; Cosentino F; De Ninno M; Catena U; De Cicco Nardone A; Moroni R; Zannoni G; Fagotti A; Scambia G
Fertil Steril; 2022 Jan; 117(1):160-168. PubMed ID: 34656305
[TBL] [Abstract] [Full Text] [Related]
9. Potential Novel ovarian cancer Treatment Targeting Myeloid-Derived Suppressor Cells.
Abiko K; Hayashi T; Yamaguchi K; Mandai M; Konishi I
Cancer Invest; 2021 Apr; 39(4):310-314. PubMed ID: 33428503
[TBL] [Abstract] [Full Text] [Related]
10. Diffuse Intratumoral Stromal Inflammation in ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
[TBL] [Abstract] [Full Text] [Related]
11. A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).
Ngoi NY; Heong V; Ow S; Chay WY; Kim HS; Choi CH; Goss G; Goh JC; Tai BC; Lim DG; Kaliaperumal N; Au VB; Connolly JE; Kim JW; Friedlander M; Kim K; Tan DS
Int J Gynecol Cancer; 2020 Aug; 30(8):1239-1242. PubMed ID: 32591370
[TBL] [Abstract] [Full Text] [Related]
12. Integrating a Next Generation Sequencing Panel into Clinical Practice in ovarian cancer.
Lee YJ; Kim D; Kim HS; Na K; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
Yonsei Med J; 2019 Oct; 60(10):914-923. PubMed ID: 31538426
[TBL] [Abstract] [Full Text] [Related]
13. Immune checkpoint inhibitors of CTLA4 and pd-1 for malignant melanoma arising in ovarian cystic teratoma: A case report.
Yano M; Asami Y; Nishikawa T; Yoshida S; Kamada K; Katoh T; Teramoto Y; Nakamura Y; Yasuda M
Medicine (Baltimore); 2018 Oct; 97(43):e12937. PubMed ID: 30412106
[TBL] [Abstract] [Full Text] [Related]
14. [Molecular Targeted Therapies for Hereditary cancer Syndrome].
Shimodaira H
Gan To Kagaku Ryoho; 2018 Apr; 45(4):587-592. PubMed ID: 29650809
[TBL] [Abstract] [Full Text] [Related]
15. diagnosis and Management of Immune Checkpoint Inhibitor-related Toxicities in ovarian cancer: A Series of Case Vignettes.
Johnson C; Jazaeri AA
Clin Ther; 2018 Mar; 40(3):389-394. PubMed ID: 29519715
[TBL] [Abstract] [Full Text] [Related]
16. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
[TBL] [Abstract] [Full Text] [Related]
17. CD25 identifies a subset of CD4⁺FoxP3⁻ TIL that are exhausted yet prognostically favorable in human ovarian cancer.
deLeeuw RJ; Kroeger DR; Kost SE; Chang PP; Webb JR; Nelson BH
Cancer Immunol Res; 2015 Mar; 3(3):245-53. PubMed ID: 25480168
[TBL] [Abstract] [Full Text] [Related]
